Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$24.01
-1.1%
$27.15
$23.25
$59.91
$3.03B0.921.95 million shs7,748 shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$22.48
+1.3%
$26.67
$20.84
$35.25
$2.25B1.911.23 million shs152,646 shs
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$3.75
-1.2%
$5.61
$3.56
$28.60
$36.41M0.76353,996 shs30,851 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.90
-0.4%
$43.17
$36.52
$70.12
$3.25B1.771.53 million shs109,614 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$824.70
+0.4%
$842.43
$711.40
$972.53
$781.96B0.343.14 million shs109,141 shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.85
-0.6%
$26.09
$24.48
$31.54
$140.91B0.6136.69 million shs1.71 million shs
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
+2.06%+0.54%-10.02%-25.70%-58.49%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+1.28%-2.97%-25.64%-16.55%-34.66%
bluebird bio, Inc. stock logo
BLUE
bluebird bio
+1.07%-4.29%-5.72%-56.83%-86.12%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-2.91%-7.60%-14.54%-4.95%-45.78%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.57%-2.51%-8.90%+4.98%+5.58%
Pfizer Inc. stock logo
PFE
Pfizer
-0.56%-4.26%-6.37%-5.89%-9.79%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.3828 of 5 stars
4.32.00.04.41.52.50.6
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.3158 of 5 stars
4.51.00.00.03.22.50.6
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.7529 of 5 stars
3.13.00.00.02.12.51.3
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
3.3139 of 5 stars
4.22.00.00.02.13.30.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8218 of 5 stars
2.45.03.34.03.42.51.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9874 of 5 stars
3.33.04.24.23.33.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.63
Moderate Buy$45.5389.66% Upside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.00
Buy$49.45119.99% Upside
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.25
Hold$51.001,261.82% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.48
Hold$73.1192.88% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7222.44% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9228.45% Upside

Current Analyst Ratings Breakdown

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$42.00 ➝ $42.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/12/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$34.00
3/10/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
3/10/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$57.00
3/10/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$40.00
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M3.86N/AN/A$1.64 per share14.64
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$63.52M35.32N/AN/A$12.04 per share1.87
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$53.12M0.69N/AN/A$35.59 per share0.11
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$35M92.89N/AN/A$22.52 per share1.68
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.36$13.44 per share61.34$15.05 per share54.80
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.22$3.90 per share6.38$15.81 per share1.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$528.63M-$1.59N/AN/AN/A-34.97%-103.11%-28.96%5/6/2025 (Estimated)
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$211.91M-$37.40N/AN/AN/A-565.74%-322.46%-53.17%5/7/2025 (Estimated)
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.4326.501.4023.51%85.24%16.19%5/1/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.628.200.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest BEAM, LLY, CRSP, PFE, APLS, and BLUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/28/2025Q4 2024
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.37-$0.29+$0.08-$0.29$197.92 million$212.50 million
2/25/2025Q4 2024
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 million
2/11/2025Q4 2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.15-$0.44+$0.71-$0.44N/AN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$0.904.00%N/AN/A N/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.92%+2.50%121.99%16 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
1.91
4.36
3.73
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
5.69
5.69
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.37
0.51
0.33
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
22.07
22.07
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
bluebird bio, Inc. stock logo
BLUE
bluebird bio
87.43%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.52 million115.93 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
51099.79 million79.33 millionOptionable
bluebird bio, Inc. stock logo
BLUE
bluebird bio
5209.72 million9.59 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
47385.77 million82.26 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer: Value Play or Past Its Prime?
WSJ report of probe to have limited impact on Pfizer, says Citi
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Trading Down 0.2% - What's Next?
U.S. prosecutors look into claim Pfizer delayed vaccine news, WSJ says
Why Pfizer Is My Largest Healthcare Position

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$24.01 -0.27 (-1.13%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$22.48 +0.29 (+1.31%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

bluebird bio stock logo

bluebird bio NASDAQ:BLUE

$3.74 -0.05 (-1.19%)
As of 09:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$37.90 -0.14 (-0.36%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$824.70 +3.03 (+0.37%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$24.85 -0.16 (-0.63%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.